基本信息
views: 5
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Personal Statement:
Our research is dedicated to the discovery of more effective therapies for the treatment of cancer, primarily breast cancer. There are several aspects to our work including drug discovery and target identification for subtypes of triple negative breast cancer and pediatric solid tumors, identification of the molecular mechanisms of the non-mitotic effects of diverse microtubule targeting drugs including their effects on oncogenic signaling pathways.
We conduct a mechanism-blind screening program to identify new anticancer leads from natural product prefractionated extracts from plants, marine organisms and fungi available from the Natural Products Branch of National Cancer Institute and from other collaborators. Leads discovered though our primary screening efforts are subject to bioassay-guided fractionation in collaboration with the Cichewicz laboratory, Institute for Natural Product Applications and Research Technologies at The University of Oklahoma. Isolated compounds are evaluated for their molecular mechanisms of action and in vivo antitumor potential. When the need arises we optimize natural product lead compounds with medicinal chemistry optimization in collaboration with Dr. Stan McHardy, Director of Medicinal Chemistry at the Center for Innovative Drug Discovery at the University of Texas at San Antonio.
Our research is dedicated to the discovery of more effective therapies for the treatment of cancer, primarily breast cancer. There are several aspects to our work including drug discovery and target identification for subtypes of triple negative breast cancer and pediatric solid tumors, identification of the molecular mechanisms of the non-mitotic effects of diverse microtubule targeting drugs including their effects on oncogenic signaling pathways.
We conduct a mechanism-blind screening program to identify new anticancer leads from natural product prefractionated extracts from plants, marine organisms and fungi available from the Natural Products Branch of National Cancer Institute and from other collaborators. Leads discovered though our primary screening efforts are subject to bioassay-guided fractionation in collaboration with the Cichewicz laboratory, Institute for Natural Product Applications and Research Technologies at The University of Oklahoma. Isolated compounds are evaluated for their molecular mechanisms of action and in vivo antitumor potential. When the need arises we optimize natural product lead compounds with medicinal chemistry optimization in collaboration with Dr. Stan McHardy, Director of Medicinal Chemistry at the Center for Innovative Drug Discovery at the University of Texas at San Antonio.
Research Interests
Papers共 284 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 7_Supplement (2023): 6397-6397
crossref(2023)
crossref(2023)
crossref(2023)
Bioorganic & medicinal chemistry (2023): 117217-117217
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
Load More
Author Statistics
#Papers: 284
#Citation: 7593
H-Index: 45
G-Index: 79
Sociability: 6
Diversity: 3
Activity: 26
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn